Delays in research and development, testing and approval
First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 22 of 44 companies on the "Worse" side.
30 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「As a research and development-focused corporate group, the Group seeks to promote efficient research and development by building external collaborative relationships centered on its joint research relationship with the University of Tsukuba. However, there can be no assurance that research and development activities will proceed as planned. The Group cannot rule out the possibility that the results initially planned for the research and development activities will not be achieved, that the start or completion of various tests will be delayed, or that obtaining marketing approval to manufacture and sell the products as medical devices will be delayed or restricted.」
While pursuing research and development through external collaboration, the Group continues to disclose the risk of delays in research and development, testing and obtaining approval. - FY2019RestatedAnnual report
「However, there can be no assurance that research and development activities will proceed as planned. The Group cannot rule out the possibility that the results initially planned for the research and development activities will not be achieved, that the start or completion of various tests will be delayed, or that obtaining marketing approval to manufacture and sell the products as medical devices will be delayed or restricted.」
The Group continues to disclose its policies for addressing the risk of delays in research and development, testing and obtaining approval, including progress management, prioritization and resource allocation. - FY2018RestatedAnnual report
「However, there can be no assurance that research and development activities will proceed as planned. The Group cannot rule out the possibility that the results initially planned for the research and development activities will not be achieved, that the start or completion of various tests will be delayed, or that obtaining marketing approval to manufacture and sell the products as medical devices will be delayed or restricted.」
The Group has reaffirmed its policies for addressing the risk of delays in research and development, testing and approval, including progress management, prioritization and changes in resource allocation. - FY2017RestatedAnnual report
「However, there can be no assurance that research and development activities will proceed as planned. The Group cannot rule out the possibility that the results initially planned for the research and development activities will not be achieved, that the start or completion of various tests will be delayed, or that obtaining marketing approval to manufacture and sell the products as medical devices will be delayed or restricted.」
The Group has reaffirmed its policies for addressing the risk of delays in research and development, testing and approval, including progress management and prioritization. - FY2016First statedAnnual report
「There can be no assurance that research and development activities will proceed as planned. The Group cannot rule out the possibility that the results initially planned for the research and development activities will not be achieved, that the start or completion of various tests will be delayed, or that obtaining marketing approval to manufacture and sell the products as medical devices will be delayed or restricted.」
The Group has also stated measures to mitigate these risks through progress management, prioritization, changes in management resources and temporary suspension.